Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vitro Biopharma's annualizedNet Income for the quarter that ended in Oct. 2022 was $-27.44 Mil. Vitro Biopharma's average total tangible assets for the quarter that ended in Oct. 2022 was $4.33 Mil. Therefore, Vitro Biopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Oct. 2022 was -633.21%.
The historical rank and industry rank for Vitro Biopharma's Return-on-Tangible-Asset or its related term are showing as below:
VTRO'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -361.9 Med: -287.14 Max: -18.54
Current: -158.3
During the past 13 years, Vitro Biopharma's highest Return-on-Tangible-Asset was -18.54%. The lowest was -361.90%. And the median was -287.14%.
VTRO's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -35.49
vs VTRO: -158.30
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vitro Biopharma Return-on-Tangible-Asset Related Terms
Vitro Biopharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vitro Biopharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vitro Biopharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitro Biopharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vitro Biopharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vitro Biopharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Oct. 2022) net income data.
What does a Return-on-Tangible-Asset of -633.21% mean?
Vitro Biopharma (VTRO) has a Return-on-Tangible-Asset of -633.21% as of Oct. 2022. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's Return-on-Tangible-Asset too high?
Vitro Biopharma's current Return-on-Tangible-Asset is -633.21%.
How does Vitro Biopharma's Return-on-Tangible-Asset compare to ?
Vitro Biopharma's Return-on-Tangible-Asset of -633.21% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current Return-on-Tangible-Asset is -633.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Return-on-Tangible-Asset of -633.21%. The current Return-on-Tangible-Asset is -633.21%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Return-on-Tangible-Asset is -633.21% as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTRO has been successfully added to your 
